By David Smith, Africa correspondent
Aug. 11, 2015 | The Guardian
Africa has achieved a year without any new cases of wild polio for the first time, but experts warn that violent insurgencies could yet prove their “achilles heel” in finally eradicating the disease.
The poliomyelitis virus attacks the nervous system and can cause irreversible paralysis within hours of infection. No cases have been identified in Africa since 11 August last year in the Hobyo district of Mudug province in Somalia, meaning that the continent is two years away from being certified polio-free.
But both Somalia and Nigeria, which also saw its last polio case in 2014, are battling Islamist militant groups – al-Shabaab and Boko Haram respectively – raising fears that vaccines will not reach children displaced by conflict.
“I just hope Boko Haram will not be the achilles heel of our work,” said Oyewale Tomori, professor of virology at the Nigerian Academy of Science, who has dedicated four decades of his life to polio research. “Unless we get rid of the insurgency, we cannot be sure we will eradicate polio.”
In Nigeria there is a target cohort of 5 million to 6 million children each year, he added, and vaccines must reach 90%-95% of them to prevent polio recurring. “Getting vaccines to displaced people will be crucial,” said Tomori.
By Rachel Held EvansDan and I will be blessed with plenty of gifts, plenty of diapers and onesies and gear (...my goodness, all the gear!)... So if you want to offer a special congratulations on our big news, jump over to my fundraising page to leave a message and a gift in support of Hope Through Healing Hands.
By Joel Musee, Frist Global Health LeaderI was lucky to have travelled to Kijabe at an exciting time; there has been an increase in awareness in the medical community about the lack of access to safe anesthesia in low-middle income countries. The GE corporation has been prescient and magnanimous in their support of the efforts by anesthesiologists at Vanderbilt to create a sustainable program to educate Kenyan nurse anesthetists on how to provide a safe anesthetic.
Aug 01 2015
By Emily duBois, Frist Global Health LeaderThe travel time was the most painstaking part of the process to return to Rwanda, not because it took me over 24 hours but because I was just so ready to be back. They say third time’s a charm so I guess we shall see. The first time I arrived was in 2009, I was as a freshly graduated young adult with hopes of changing the world. The Peace Corps was instrumental in curbing my idealism and provided a better picture of what development and progress looks like.
By Sarah Boseley, The Guardian Health editor
July 31, 2015 | The Guardian
A vaccine against Ebola has been shown to be 100% successful in trials conducted during the outbreak in Guinea and is likely to bring the west African epidemic to an end, experts say.
The results of the trials involving 4,000 people are remarkable because of the unprecedented speed with which the development of the vaccine and the testing were carried out.
Scientists, doctors, donors and drug companies collaborated to race the vaccine through a process that usually takes more than a decade in just 12 months.
“Having seen the devastating effects of Ebola on communities and even whole countries with my own eyes, I am very encouraged by today’s news,” said Børge Brende, the foreign minister of Norway, which helped fund the trial.
“This new vaccine, if the results hold up, may be the silver bullet against Ebola, helping to bring the current outbreak to zero and to control future outbreaks of this kind. I would like to thank all partners who have contributed to achieve this sensational result, due to an extraordinary and rapid collaborative effort,” he said on Friday.
There have been a total of 27,748 cases of Ebola in Guinea, Liberia and Sierra Leone up to 26 July, with 11,279 reported deaths, although the outcome of many cases is unknown and the toll will be significantly higher. In the week ending 26 July, there were just four new cases in Guinea and three in Sierra Leone.
By Harriet Alexander
July 24, 2015 | The Telegraph
The vaccine, named Mosquirix, was given the green light on Friday after more than 30 years of research, detailed in 230,000 pages of data. It now means that the vaccine will be examined by the World Health Organisation and, if approved, could be administered to children across Africa within the next few years.
"It's massively significant," said Allan Pamba, vice president for pharmaceuticals in East Africa for GlaxoSmithKline (GSK), which has spent more than $356 million (£230m) to date on finding a vaccine. GSK expects to invest a further $200 to $250 million until development is completed. In January 2001, GSK and PATH Malaria Vaccine Initiative, with grant monies from the Bill & Melinda Gates Foundation to PATH, entered into a public-private partnership to develop a vaccine. PATH has invested more than $200 million, much of it from the Gateses.
"Malaria has been incredibly difficult to crack. It's been tremendously frustrating. But we are all immensely proud to have reached this milestone."
July 24, 2015 | Belmont University
When doctorate of nursing practice student Jennifer Quigley realized she would be the first Belmont recipient of the Frist Global Health Fellowship, she said she was eager to use her passion for global health to implement a plan for teaching health care providers in Cap-Haitien, Haiti a modern method of natural family planning. Her trip was born of a partnership between Belmont’s College of Health Sciences and Nursing and the organization Hope Through Healing Hands, which was founded by Former U.S. Senate Majority Leader Bill Frist, M.D.
Although the goal of the trip was to assist the Haitian people, Quigley was quick to say the trip was life-changing for her, as well. “I learned so much more from the Haitian people than they learned from me. I have never seen a more joyous people, full of life and love, and each was eager to show me love. Though they did not have much, I never went hungry, and I always had water. They joyfully give, even if they have so little to start with,” she said. “I also had the opportunity to deliver a baby, with only one other nurse, no drugs and not sterile equipment — only a clean room and the two of us. It was an experience I will hold with me for the rest of my life.”